211 related articles for article (PubMed ID: 20886379)
1. Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience.
Igarashi N; Chou T; Hirose T; Imai Y; Ishiguro T
Int J Hematol; 2010 Oct; 92(3):518-23. PubMed ID: 20886379
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Takamatsu Y; Sunami K; Hata H; Nagafuji K; Choi I; Higuchi M; Uozumi K; Masaki Y; Tamura K;
Int J Hematol; 2010 Oct; 92(3):503-9. PubMed ID: 20824401
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.
Ohguchi H; Sugawara T; Ishikawa I; Okuda M; Tomiya Y; Yamamoto J; Onishi Y; Fujiwara Yamada M; Ishizawa K; Kameoka J; Harigae H
Int J Hematol; 2009 Apr; 89(3):342-347. PubMed ID: 19296199
[TBL] [Abstract][Full Text] [Related]
5. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
[TBL] [Abstract][Full Text] [Related]
7. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
[TBL] [Abstract][Full Text] [Related]
8. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
[TBL] [Abstract][Full Text] [Related]
9. Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland.
Taverna C; Voegeli J; Trojan A; Olie RA; von Rohr A
Swiss Med Wkly; 2012; 142():w13562. PubMed ID: 22544478
[TBL] [Abstract][Full Text] [Related]
10. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Mangiacavalli S; Pochintesta L; Pascutto C; Cocito F; Pompa A; Cazzola M; Corso A
Am J Hematol; 2013 Feb; 88(2):102-6. PubMed ID: 23224960
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; San-Miguel JF; Bladé J; Boccadoro M; Cavenagh J; Dalton WS; Boral AL; Esseltine DL; Porter JB; Schenkein D; Anderson KC;
N Engl J Med; 2005 Jun; 352(24):2487-98. PubMed ID: 15958804
[TBL] [Abstract][Full Text] [Related]
12. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Richardson PG; Sonneveld P; Schuster M; Irwin D; Stadtmauer E; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Miguel JS; Bladé J; Boccadoro M; Cavenagh J; Alsina M; Rajkumar SV; Lacy M; Jakubowiak A; Dalton W; Boral A; Esseltine DL; Schenkein D; Anderson KC
Blood; 2007 Nov; 110(10):3557-60. PubMed ID: 17690257
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK
J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450
[TBL] [Abstract][Full Text] [Related]
14. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
[TBL] [Abstract][Full Text] [Related]
16. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Ogawa Y; Tobinai K; Ogura M; Ando K; Tsuchiya T; Kobayashi Y; Watanabe T; Maruyama D; Morishima Y; Kagami Y; Taji H; Minami H; Itoh K; Nakata M; Hotta T
Cancer Sci; 2008 Jan; 99(1):140-4. PubMed ID: 17970782
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
[TBL] [Abstract][Full Text] [Related]
18. Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
Freimann H; Calderoni A; Cornu P; Olie R
Swiss Med Wkly; 2007 Jun; 137(21-22):317-22. PubMed ID: 17629810
[TBL] [Abstract][Full Text] [Related]
19. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
Jagannath S; Durie BG; Wolf JL; Camacho ES; Irwin D; Lutzky J; McKinley M; Potts P; Gabayan AE; Mazumder A; Crowley J; Vescio R
Br J Haematol; 2009 Sep; 146(6):619-26. PubMed ID: 19622094
[TBL] [Abstract][Full Text] [Related]
20. Expanding role of bortezomib in multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J
Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
